Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
Breccia M, Celant S, Olimpieri PP, Olimpieri OM, Pane F, Iurlo A, Cirilli A, Colatrella A, Gozzo L, Pugliese S, Summa V, Foggi P, Corradini P, Russo P; AIFA Monitoring Registries Group. Breccia M, et al. Among authors: olimpieri om. Ann Hematol. 2021 Feb;100(2):481-485. doi: 10.1007/s00277-021-04406-1. Epub 2021 Jan 7. Ann Hematol. 2021. PMID: 33415425
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).
Breccia M, Olimpieri PP, Olimpieri O, Pane F, Iurlo A, Foggi P, Cirilli A, Colatrella A, Cuomo M, Gozzo L, Summa V, Corradini P, Russo P; AIFA’s Monitoring Registries Group. Breccia M, et al. Cancer Med. 2020 Jun;9(12):4160-4165. doi: 10.1002/cam4.3071. Epub 2020 Apr 22. Cancer Med. 2020. PMID: 32319737 Free PMC article.
Real world data to identify target population for new CAR-T therapies.
Belleudi V, Trotta F, Fortinguerra F, Poggi FR, Olimpieri O, Santelli E, Cozzi I, Michelozzi P, Addis A. Belleudi V, et al. Pharmacoepidemiol Drug Saf. 2021 Jan;30(1):78-85. doi: 10.1002/pds.5165. Epub 2020 Nov 11. Pharmacoepidemiol Drug Saf. 2021. PMID: 33108004
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.
Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G, Pogliani EM, Olimpieri OM, Fioritoni G, Musolino C, Cilloni D, Sivera P, Barosi G, Finazzi MC, Tollo SD, Demuth T, Barbui T, Rambaldi A. Finazzi G, et al. Among authors: olimpieri om. Br J Haematol. 2013 Jun;161(5):688-694. doi: 10.1111/bjh.12332. Epub 2013 Apr 10. Br J Haematol. 2013. PMID: 23573950 Free article. Clinical Trial.
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: olimpieri om. ESMO Open. 2019 Sep 8;4(5):e000570. doi: 10.1136/esmoopen-2019-000570. eCollection 2019. ESMO Open. 2019. PMID: 31555488 Free PMC article. Review.
A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment.
Marchesi F, Cenfra N, Altomare L, Dessanti ML, Mecarocci S, Cerchiara E, Rago A, D'Andrea M, Tomarchio V, Olimpieri OM, Tirindelli MC, Mengarelli A, Petti MC, Avvisati G, Cimino G. Marchesi F, et al. Among authors: olimpieri om. J Geriatr Oncol. 2013 Jul;4(3):242-8. doi: 10.1016/j.jgo.2013.04.003. Epub 2013 May 7. J Geriatr Oncol. 2013. PMID: 24070462
High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.
Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E, Renzi D, Micera A, Balzamino BO, Bonini S, Onetti Muda A, Avvisati G. Marchesi F, et al. Among authors: olimpieri om. Hematol Oncol. 2015 Jun;33(2):110-2. doi: 10.1002/hon.2142. Epub 2014 Apr 8. Hematol Oncol. 2015. PMID: 24711044 No abstract available.
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
Breccia M, Olimpieri PP, Celant S, Olimpieri OM, Pane F, Iurlo A, Summa V, Corradini P, Russo P. Breccia M, et al. Among authors: olimpieri om. Ann Hematol. 2023 May;102(5):1257-1259. doi: 10.1007/s00277-023-05168-8. Epub 2023 Mar 13. Ann Hematol. 2023. PMID: 36914888 No abstract available.
11 results